Gleevec/Glivec

Novartis' orphan drug Tasigna wins EU expanded indication

Gilvec/Gleevec (imatinib).

Alcon spin-out more likely but not imminent, says Novartis

The growth of these products helped counteract the continued sales declines for cancer drug Gleevec/Glivec (imatinib), which fell to $445m from $834m a year ago, and allowed Novartis to post

Prix Galien opens for entries with new award

Previous UK Prix Galien winners include well-known brands such as Viagra, Herceptin, Glivec, Xolair, Bexero, Cervarix and Gardasil.

Vas Narasimhan takes top Novartis job on Jimenez departure

The handover comes as Novartis is emerging from a difficult couple of years following the patent expiry for cancer blockbuster Glivec/Gleevec (imatinib), difficulties at its eyecare division Alcon - which recently

Alcon's return to growth gives Novartis 'options', says CEO

Alcon's recovery came against the backdrop of a 2% fall in group sales to $12.2bn - mainly because of continued generic competition to cancer blockbuster Gleevec (imatinib) which drove sales

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]